WebiFACT study team. Drug-drug interactions between the use of feminizing hormone therapy and pre-exposure prophylaxis among transgender women: The iFACT study [TUPDX0107LB]. 22nd International AIDS Conference (AIDS 2024) Amsterdam, Netherlands. 23-27 July 2024. Resumen: Hiransuthikul et al. presentaron los resultados … Web14 mrt. 2024 · The data that support the findings of this study may be available from the corresponding author upon reasonable request and in compliance with relevant institutional policies. REFERENCES 1Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis.
CSIRO PUBLISHING Sexual Health
Web18 mrt. 2024 · Investigative Journalists’ Team “iFact” (Georgia) was founded by a women journalists team in 2016, and includes two investigative newsrooms across Georgia. … Webنبذة عني. I am an engineer, searcher and consultant in ecology and environment, with a very good academic background and several distinctions, very versatile and with a lot of … ergo organic baby
New research results reveal progress in HIV prevention
Web30 jun. 2024 · Journal of the International AIDS Society Volume 23, Issue S3e25540 Supplement: Research Article Open Access Evaluation of a pre-exposure prophylaxis programme for men who have sex with men and transgender women in Thailand: learning through the HIV prevention cascade lens Reshmie A Ramautarsing, Reshmie A … Web1 feb. 2024 · This study summarizes 13 years’ experience following people with Human Immunodeficiency Virus Type 2 (HIV-2) receiving antiretroviral therapy (ART) in Senegal. Earlier ART initiation and more modern therapeutic regimens have improved outcomes. However, HIV-2 treatment remains suboptimal, and viral suppression rates remain below … WebDrug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. Our study demonstrated lower blood … ergopearl